Challenges in the Management of EGFR-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors

Publisher： Karger

E-ISSN： 1423-0232|87|2|83-94

ISSN： 0030-2414

Source： Oncology, Vol.87, Iss.2, 2014-07, pp. : 83-94

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

By  

Oncology, Vol. 86, Iss. 2, 2014-01 ,pp. : 86-93

Karger

Access to resources Recommend Favorite

Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer

By  

CANCER, Vol. 120, Iss. 15, 2014-08 ,pp. : 2289-2298

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4325-4332

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations

By  

Oncology Research and Treatment, Vol. 40, Iss. 1-2, 2017-01 ,pp. : 7-13

Karger

Access to resources Recommend Favorite

Volumetric tumor growth in advanced non‐small cell lung cancer patients with EGFR mutations during EGFR‐tyrosine kinase inhibitor therapy

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3761-3768

John Wiley & Sons Inc

Access to resources Recommend Favorite